Methadone vs placebo
Participants experiencing anyserious adverseevents · adults with chronic neuropathic pain
1 finding from 1 review
- no estimate extractedStudies not reportedVery low
Findings
What do systematic reviews say?
4 questions · 4 findings · 3 reviews · Pain, Palliative and Supportive Care
No studies found 1 · 25%GRADE not reported 0 · 0%Very low 1 · 25%Low 1 · 25%Moderate 1 · 25%High 0 · 0%
Methylnaltrexone vs placebo
Serious adverse eventsi · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone may leads to lower serious adverse eventsi compared with placebo (low certainty).
1 finding from 1 review
- Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes onlyRR 0.59 [0.38, 0.93]2 studies · 364 participantsLow
Lower‐dose methylnaltrexone vs higher dose
Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
- Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
High‐dose corticosteroids vs moderate‐dose or no corticosteroids
Serious adverse events · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids probably leads to higher serious adverse events compared with moderate‐dose or no corticosteroids (moderate certainty).
1 finding from 1 review
- Interventions for the treatment of metastatic extradural spinal cord compression in adults 2015 · Cochrane Headline outcomes onlyRR 8.02 [1.03, 62.37]2 studies · 77 participantsModerate